Andrew J. Pierce
YOU?
Author Swipe
View article: Ritualistic Male–Male Combat of the Northern King Cobra (<scp><i>Ophiophagus hannah</i></scp>) in Thailand
Ritualistic Male–Male Combat of the Northern King Cobra (<span><i>Ophiophagus hannah</i></span>) in Thailand Open
Ritualistic male–male combat is exhibited by several snake species, and is accepted as a given natural history trait for king cobras. However, there are no detailed accounts of combat behavior in king cobras in the primary literature, desp…
View article: Quantifying Resilience in Single-Host/Single-Virus Infections
Quantifying Resilience in Single-Host/Single-Virus Infections Open
Due to theoretical and practical applications in biomedical, environmental, and industrial microbiology, robust metrics for quantifying the virulence of pathogens is vital. For many virus–host systems, multiple virus strains propagate thro…
View article: Quantifying Resilience in Single-Host/Single-Virus Infections
Quantifying Resilience in Single-Host/Single-Virus Infections Open
Developing metrics for quantifying the virulence of pathogens (e.g., viruses) is a historical and recently reinvigorated topic of research interest with both theoretical and practical applications in medical, industrial, and environmental …
View article: Data from Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
Data from Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study Open
Purpose:This study reports the safety, tolerability, MTD, recommended phase II dose (RP2D), pharmacokinetic/pharmacodynamic profile, and preliminary antitumor activity of ceralasertib combined with carboplatin in patients with advanced sol…
View article: Supplementary Data from Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study
Supplementary Data from Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study Open
Supplementary material
View article: PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets
PD-1/LAG-3 co-signaling profiling uncovers CBL ubiquitin ligases as key immunotherapy targets Open
View article: Solving selectivity issues in LBAs: case study using Gyrolab to quantify CB307, a bispecific Humabody in human serum
Solving selectivity issues in LBAs: case study using Gyrolab to quantify CB307, a bispecific Humabody in human serum Open
Aim: Endogenous interferents can cause nonselectivity in ligand binding pharmacokinetic assays, leading to inaccurate quantification of drug concentrations. We describe the development of a Gyrolab immunoassay to quantify a new moda…
View article: Supplementary Table 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Table 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Table 1: Mouse PK summary statistics
View article: Supplementary Figure 3 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Figure 3 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Figure 3: PK/TK dosing strategies
View article: Supplementary Figure 11 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Figure 11 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Figure 11: Vipivotide tetraxetan does not interfere with CB307 activity
View article: Data from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Data from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Purpose:CD137 is a T- and NK-cell costimulatory receptor involved in consolidating immunologic responses. The potent CD137 agonist urelumab has shown clinical promise as a cancer immunotherapeutic but development has been hampered by on-ta…
View article: Supplementary Figure 8 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Figure 8 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Figure 8: Spheroid end-of-study T=240h images
View article: Supplementary Figure 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Figure 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Figure 1: Validation of CD137 immunohistochemistry
View article: Supplemental Methods 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplemental Methods 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplemental Methods
View article: Supplementary Figure 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Figure 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Figure 1: Validation of CD137 immunohistochemistry
View article: Supplementary Video 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Video 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Video 1
View article: Data from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Data from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Purpose:CD137 is a T- and NK-cell costimulatory receptor involved in consolidating immunologic responses. The potent CD137 agonist urelumab has shown clinical promise as a cancer immunotherapeutic but development has been hampered by on-ta…
View article: Supplementary Figure 2 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Figure 2 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Figure 2: aCD137 antibody clone E6Z7F specificity
View article: Supplementary Figure 10 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Figure 10 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Figure 10: hPSMA expression on RP1 tumour cells is lost over time, even in tumours dosed with HSA only
View article: Supplementary Video 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Video 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Video 1
View article: Supplementary Figure 5 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Figure 5 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Figure 5: CB307 binding to cell-presented targets
View article: Supplementary Figure 8 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Figure 8 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Figure 8: Spheroid end-of-study T=240h images
View article: Supplementary Table 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Table 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Table 1: Mouse PK summary statistics
View article: Supplementary Figure 3 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Figure 3 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Figure 3: PK/TK dosing strategies
View article: Supplementary Figure 10 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Figure 10 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Figure 10: hPSMA expression on RP1 tumour cells is lost over time, even in tumours dosed with HSA only
View article: Supplementary Figure 7 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Figure 7 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Figure 7: CRISPR-mediated PD-L1 gene knock-out in DU145-PSMA cells
View article: Supplementary Figure 6 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Figure 6 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Figure 6: Synergy quantitation for CB307 / pembrolizumab combination
View article: Supplementary Figure 11 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Figure 11 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Figure 11: Vipivotide tetraxetan does not interfere with CB307 activity
View article: Supplemental Methods 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplemental Methods 1 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplemental Methods
View article: Supplementary Figure 9 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors
Supplementary Figure 9 from CB307: A Dual Targeting Costimulatory Humabody V<sub>H</sub> Therapeutic for Treating PSMA-Positive Tumors Open
Supplementary Figure 9: Neuroendocrine Differentiation Phenotypes in Prostate Cancer Liver Metastases